Chanelle founder invests €100k in Redesdale Group
Michael Burke has taken a stake in a firm that will seek to acquire or invest in early stage food and wellness businesses
Malin shareholders in line for windfall after €119 million cash boost
Dublin-based biotech investment fund said €45 million of the proceeds from the sale will be used to repay a European Investment Bank loan, with the remaining cash to be returned to shareholders later this year
Amryt seeks to have rare condition drug approved for payment
The Dublin company is in discussion with regulators in Britain and France to have metreleptin, a treatment for abnormal distribution of fat in the body, approved for payment reimbursement
Icon to restore staff pay as business recovers from virus
Clinical trials firm reported 10.8% drop in revenues for the three months to the end of June
Comment: Cutting-edge pharma research can bring investment to Ireland
We have the potential to become Europe’s go-to destination for the development of advanced therapy medicinal products
Sandra Gannon: We must act now to stop medicines running out
The essential ingredients for common drugs are largely produced in the countries worst-hit by Covid-19. We could soon be facing shortages of antibiotics, paracetamol, statins and other medication
Equine vet company Epona licences diagnostic blood test
Zoetis, the animal pharma giant, has acquired exclusivity on Stablelab, a hand-held test that quickly assesses the severity of infections in horses
Open Orphan chief to underwrite part of £30m hVivo takeover
Friel ready to stump up €3m of fundraising for purchase of British clinical trials firm
UDG posts operating profits of $158m as acquisition spree continues
Dublin-based healthcare group buys US agency Canale Communications for up to $31m
Court orders Molex to hand over documents on employee health claims
A former worker at the US firm‘s Shannon plant claims his Parkinson’s disease is linked to exposure to dangerous chemical
Pharma sector calls for drug prices to build in real-world value
The pharmaceutical industry wants future negotiations on drug pricing to include the extent to which drugs prevent costly hospital stays and details of other societal benefits they generate